Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of self-administered Adasuve outside the hospital setting in agitated adults with schizophrenia or bipolar disorder
2015-003331-36Phase 4Completed
- Sponsor
- Ferrer
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of loxapine in schizophrenia, bipolar disorder (BD) and agitation, sponsored by Ferrer. Primary endpoint: Frequency of adverse events related to Adasuve. Started Dec 2015; status: completed.
02
Drugs
loxapine
03
Conditions
schizophreniabipolar disorder (BD)agitation
Beyond the preview
Go deeper on 2015-003331-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003331-36.